Videos

Pharmacists can improve statin adherence and refine triglyceride management by leveraging patient-centered counseling, adherence strategies, and updated guideline recommendations prioritizing statins and targeted adjunctive therapies.

The growing need to integrate pharmacists into sports medicine teams, where their expertise in medication safety, chronic disease management, and supplements can significantly enhance athlete care and performance.

This interview highlights the importance of integrating holistic health, lifestyle coaching, and medication management to create more effective, patient-centered care.

Pharmacists play a critical role in bridging athlete performance and safety, emphasizing foundational health habits, addressing supplement misconceptions, and supporting mental health through frequent, trusted patient interactions.

Travis Tygart, JD, discusses the growing risks of supplements and the critical need for education and vigilance to protect athletes and uphold clean sport.

Nilhan Uzman, MS, BPharm discusses how pharmacists elevate athlete care, guiding safe medicines and supplements, debunking “natural” myths, and strengthening clean sport teams.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR-T and bispecifics, and selective smoldering treatment.

Kyle Fischer, PharmD, explains navigating payer hurdles, supporting adherence, and improving coordination in ILD and PAH care.

Amy Seung outlines her priorities for leading HOPA through evolving therapies, workforce challenges, and expanding pharmacy roles.

The panel examined the evolving reimbursement landscape for RSV vaccines, with a focus on the positive impact of the Inflation Reduction Act for Medicare Part D beneficiaries.

The panel discussed the expected side effects associated with RSV immunization, including common local reactions like pain and swelling at the injection site, as well as systemic effects such as fatigue, fever, and muscle aches.

This week's episode highlights new data on the newly approved oral GLP-1, orforglipron, the growing role of sports pharmacists, and a higher-dose regimen FDA approval for spinal muscular atrophy.

Pharmacist Kyle Fischer, PharmD, APh, explains how antifibrotic therapy, drug interactions, and pharmacist–physician collaboration guide ILD care.

Learn how CDK4/6 inhibitor schedules vary and how pharmacists boost adherence, manage nausea, labs, QTc, and drug interactions.

How CDK4/6 inhibitors stack up in metastatic HR+ breast cancer, with trial survival data, real‑world tolerability, and visceral crisis caveats.

Pharmacists play a central role in implementing new dyslipidemia guidelines, including ApoB testing, earlier risk assessment, and expanded use of combination lipid-lowering therapy.

Erin Dorval, PharmD, highlights the pharmacist’s role in safe athlete pain management, emphasizing appropriate NSAID use, alternative therapies, and emerging trends like personalized care and wearable-driven performance optimization.

Ahead of the Sports Pharmacy Summit, Erin Dorval, PharmD, highlights the pharmacist’s role in optimizing athlete performance and recovery through safe medication use, careful supplement evaluation, and a holistic, risk-minimizing approach to care.

The panel examined practical strategies for coadministering respiratory syncytial virus vaccines with those for other respiratory illnesses, such as flu and COVID-19.

The panel examined practical strategies for following up with vaccine-hesitant patients, emphasizing the critical role of health information technology in this process.

Joseph Saseen, PharmD, addresses statin intolerance and misinformation and provides a look at aggressive new LDL targets and emerging therapies not yet captured in the 2026 guidelines.

Deucravacitinib offers a targeted, well-tolerated oral option for patients with psoriatic arthritis, with efficacy comparable to biologics and meaningful benefits in patient-reported outcomes.

NABP weighs OET and best-section scoring to ease FPGEE path while boosting pass rates and safeguarding patient care.

Learn how teams flag adjuvant CDK4/6 candidates at diagnosis, avoid patients slipping through cracks, and improve real-world use.

Five-year NATALEE updates show ribociclib boosts invasive disease-free survival in broader early breast cancer risk groups, guiding therapy choice.

A FINEARTS-HF subgroup analysis shows patients with HFpEF and comorbid sleep apnea face a 43% higher adjusted cardiovascular risk.

Experts from NABP and the Arkansas State Board of Pharmacy explain how Pulse by NABP equips pharmacists and regulators with real-time drug supply chain verification tools.

Eduardo Martinez Sanchez, PharmD, CPh, BCPS, BCACP, discusses key counseling points, the importance of individualizing disease management, and promising therapies to keep an eye on.